QS-21 and IL-12 as an adjuvant combination

Details QS-21 and IL-12 as an adjuvant combination QS-21 and IL-12 as an adjuvant combination

2008-05-20

2008-05-20

Rao, Manjunath (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C424S204100, C424S206100, C424S211100, C424S234100, C424S283100, C424S725000

Reexamination Certificate

active

07374751

ABSTRACT:
Adjuvant compositions comprising an effective amount IL-12 and QS-21 are disclosed. Immunogenic, vaccine and pharmaceutical compositions comprising a mixture of antigen and an adjuvant composition comprising an effective amount of IL-12 and QS-21 are also disclosed. These compositions elicit functional cell-mediated and humoral immune responses against at least one antigen. Methods of using the disclosed compositions are also disclosed.

REFERENCES:
patent: 4912094 (1990-03-01), Myers et al.
patent: 5057540 (1991-10-01), Kensil et al.
patent: 5723130 (1998-03-01), Hancock et al.
patent: 6071893 (2000-06-01), Graham et al.
patent: 6375945 (2002-04-01), Boon et al.
patent: 6514503 (2003-02-01), Gizurarson et al.
patent: 6929794 (2005-08-01), Mills et al.
patent: WO9610423 (1996-04-01), None
patent: WO9611019 (1996-04-01), None
patent: WO9940937 (1999-08-01), None
Schoenhaut et al., J Immunol Jun. 1, 1992;148(11):3433:40.
Silla et al., European Cytokine Network Jun. 1999 10(2):181-90.
Singh et al.,Nat Biotechnol. Nov. 1999;17(11):1075-81.
Yoshida et al., (Mol Cell Biochem. Jun. 7, 1996;159(1):73-80. Abstract Only.
Abd-Elfattah et al., Ann Thorac Surg Nov. 1999;68(5):1954-9.
Dertzbaugh, Plasmid 1998;39(2):100-13, Review.
Laver et al., Cell. May 18, 1990; 61:553-556.
Barlow et al., Nature. Aug. 21, 1986; 33:747-748.
Weinberg et al., J Immunol Jan. 1, 1988;140(1):294-9.
Datta et al, Immunol Rev Jun. 2004;199:217-26, Abstract Only.
Silla, et al., “Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL,” European Cytokine Network, 10(2):181-189 (1999).
Hancock, et al., “QS-21 synergizes with recombinant interleukin-12 to create a potent adjuvant formulation for the fusion protein of respiratory syncytial virus,” Viral Immunology, 13(4):503-509 (2000).

Affiliated with

Also associated with

Rating

QS-21 and IL-12 as an adjuvant combination does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with QS-21 and IL-12 as an adjuvant combination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and QS-21 and IL-12 as an adjuvant combination will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2802255